Private Market View

Ubicept

Boston, MA · Founded 2021 · Privately Held (backing)

Last price · $/share
Implied valuation
$43.0M
Total raised
$12.7M
Last round
Seed Round
Jun 2025

Key facts

  • Ubicept’s last known valuation is $43.0M (Jun 2025).
  • It has raised $12.7M across 2 recorded rounds; the latest was Seed Round ($4.6M) in Jun 2025.
  • Notable investors include Alumni Ventures, gBETA, E14 Fund, The Engine, Massachusetts Institute of Technology17 tracked in total.
  • Ubicept has filed 2 Form Ds with the SEC since 2023, most recently Jun 2025 ($4.6M sold to 9 investors).
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·Post-money valuations for all 2 rounds
  • ·The complete investor list — 17 names
  • ·Watchlist + deal alerts for Ubicept
Create free account
No card required

Funding rounds

2 rounds
Jun 2025Seed Round$4.6MSEC filing
May 2023Early Stage VC$7.8MSEC filing

About Ubicept

Developer of image sensors designed for advanced computer vision algorithms to capture motion. The company offers advanced photon-level processing algorithms, sensor-agnostic integration, and a development kit with cameras to capture clear images in extreme lighting, high-motion, and around-corner scenarios, enabling industries like automotive and robotics to achieve reliable perception in challenging environments.

Sector
Information Technology
HQ
Boston, MA, United States
Founded
2021
Employees
16
Ownership
Privately Held (backing)
PA Mark — not yet priced

Ubicept doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Ubicept shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Ubicept in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.